Serge Saxonov - 02 Nov 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol
TXG
Transactions as of
02 Nov 2021
Net transactions value
-$2,357,574
Form type
4
Filing time
04 Nov 2021, 19:10:42 UTC
Previous filing
07 Oct 2021
Next filing
24 Nov 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $26,248 +5,208 +0.58% $5.04* 897,344 02 Nov 2021 Direct F1
transaction TXG Class A Common Stock Options Exercise $34,865 +3,037 +0.34% $11.48 900,381 02 Nov 2021 Direct F1
transaction TXG Class A Common Stock Sale $519,410 -3,241 -0.36% $160.26 897,140 02 Nov 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale $957,687 -5,946 -0.66% $161.06 891,194 02 Nov 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale $908,962 -5,613 -0.63% $161.94 885,581 02 Nov 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale $32,628 -200 -0.02% $163.14 885,381 02 Nov 2021 Direct F1
holding TXG Class A Common Stock 4,498 02 Nov 2021 See footnote F5
holding TXG Class A Common Stock 89,960 02 Nov 2021 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -5,208 -8.2% $0.000000 58,532 02 Nov 2021 Class A Common Stock 5,208 $5.04 Direct F1, F7
transaction TXG Stock Option (right to buy) Options Exercise $0 -3,037 -5.6% $0.000000 51,633 02 Nov 2021 Class A Common Stock 3,037 $11.48 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $159.60 to $160.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $160.60 to $161.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $161.63 to $162.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F6 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F7 This option, originally for 250,000 shares, of which 191,468 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F8 This option, originally for 145,786 shares, of which 94,153 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.